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Abstract
Antibiotic resistance is one of the leading medical crises in the world today. The antibiotic resistant strains
are presenting a serious threat to the health of individuals. The strains of Staphylococcus aureus, which are
untreatable by any existing antibiotics, were developed already. According to World Health Organization,
4,80,000 people develop drug resistant tuberculosis each year, globally. Ever since the antibiotics were discovered,
the resistant strains have been challenging the efficacy of the developed antibiotics. This crisis has been due to
the lack of new drugs and due to the misuse of the existing antibiotics. This review presents the emergence,
molecular mechanisms of developing resistance, and strategies for minimizing the resistance.

Introduction
Antibiotics play a major role in the treatment
and prevention of bacterial infections. They are
also helpful in preventing various postoperative
infections, for cancer patients who are receiving
chemotherapy, during organ transplantation and for
HIV infected patients to prevent pneumonia.1
The antibiotic resistant strains are often termed as
‘superbugs’. The genes of the superbugs will allow
the microbes to survive even in the therapeutic
levels of antibiotics. Centres for disease control and
prevention (CDC) classified the resistant strains as
urgent, severe, and concerning threats. Clostridium
difficile (CDIFF) and Neisseria gonorrhoeae
strains fall under the urgent threat. Methicillin
resistant Staphylococcus aureus (MRSA) and
vancomycin resistant Enterococcus (VRE) are some
of the strains, that come under the severe threats.
Vancomycin resistant Staphylococcus aureus is the
one concerning threat.1
The root cause for developing antibiotic resistance
include, the misuse and the overuse of antibiotics,
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incorrect duration of therapy, wrong choice,
extensive use of antibiotics in livestock and lack of
new antibiotics. The overuse of antibiotics is the
primary reason for the development of resistant
strains. Improper regulation and dispensing
antibiotics over the counter promotes overuse.2
Prescribing wrong antibiotic will lead to potential
side effects. Antibiotics are used in livestock for
the prevention of infections and to improve health.
These are consumed by humans when they take food,
which in turn leads to adverse health consequences.
The practice of using antibiotics on fruit trees to
act as pesticide will also play a role in developing
resistance. Finally, the lack of new antibiotics due
to less investment resulted in the development of
resistance.
Emergence
The discovery of penicillin in 1928 started the
golden era for antibiotics. They were used to treat
severe infections and it saved many lives. Penicillin
was successful in treating many bacterial infections.3
However, the resistant strains to penicillin were
developed and became a concerning threat. The
discovery of beta lactam antibiotics solved this
problem, but MRSA was identified after 10 years.
Eventually, the resistance has been developed for all
known antibiotics. Vancomycin was developed for
treating this MRSA infection.
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Carbapenems are useful in treating multi drug
resistant bacteria. They are a class of beta lactam
antibiotics and kill bacteria by inhibiting cell wall
synthesis. They are broad-spectrum antibiotics,
used to treat the infections by resistant strains
like Pseudomonas aeruginosa, Escherichia coli,
and Acinetobacter species. Yong et. al. described a
strain of Klebsiella pneumoniae, that is capable of
producing metallo-beta-lactamase enzyme (MBL).
Because of this enzyme, it became resistant to
carbapenems which made difficult to treat their
infection. This strain was identified in Swedish
patient of Indian origin who acquired urinary tract
infection.4 This enzyme was named as New Delhi
metallo-beta-lactamase-1 (NDM-1) as a patient
acquired it from India.
Mechanisms of antibiotic resistance
Antibiotic resistance can be developed by several
mechanisms. Broadly, it may be due to modification
or inactivation of antibiotic or decreased uptake
of antibiotics. The bacteria become resistant to a
specific antibiotic either by intrinsic mechanisms or
by acquiring resistance genes from other bacteria.5
Bacteria contain several genes, which would lead
to intrinsic bacterial resistance and some bacteria
acquire these genes and become resistant. The
various mechanisms by which bacteria can acquire
resistance is shown in Figure 1.

Figure 1: Mechanisms of antibiotic resistance

A. Inactivation of antibiotics
Hydrolysis of antibiotics by enzymes produced
by bacteria is the most common way to achieve
resistance in bacterial strains. The group of
beta lactam antibiotics are prone to lysis by the

enzyme beta lactamase. Diverse range of enzymes
specifically beta lactamases, have been developed
which are capable of lysing cephalosporins,
penicillins, carbapenems and monobactams.6
Transfer of plasmid from one bacteria to another
lead to the development of resistance.7 The resistant
strains were developed, which were even capable
of degrading powerful member of beta lactam
antibiotics group, the carbapenemes. These strains
produce MBL-1 to degrade carbapenems. Several
classes of enzymes have been characterized, which
can degrade aminoglycosides and macrolides.
The beta lactam antibiotics exert their action by
binding to penicillin binding proteins (PBP). The
PBPs are a group of proteins located on the bacterial
cell membrane, and are essential for the cross
linking of the bacterial cell wall. The beta lactams
when bound to PBPs prevent them from performing
their function, thereby leading to the inhibition of
cell wall synthesis. The mechanism of beta lactam
antibiotics is to bind penicillin-binding protein,
which inhibits the cell wall synthesis. Destruction
of beta lactam ring results in the loss of ability to
bind the penicillin-binding proteins. The examples
include penicillin resistant strains of Staphylococci
and cephalosporin resistant Enterobacteriaceae.
B. Modification of structure of antibiotic
Accurate binding of antibiotic to target protein
depends on the structure of antibiotic. Any change
in the structure prevents its binding to target
protein.8 Changes are made by adding chemical
groups like phosphate and hydroxyl to antibiotics.
These kinds of modifications are particularly seen
in aminoglycosides like streptomycin, amikacin, and
kanamycin, in which the structure of the antibiotic
is modified. Hence, it cannot bind the ribosome and
affect the protein synthesis. Example is the resistant
species of Mycobacterium.
C. Altered target
The binding regions were altered in resistant bacterial
species either by mutation in the genes coding
target protein or by modification of target protein.
The changes prevent binding to target protein
and confers resistance.9 This kind of resistance
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was developed in almost all antibiotic classes like
aminoglycosides, quinolones, glycopeptides, and
beta lactams due to mutations and transformation.
The examples include vancomycin resistant strains
of enterococci.
D. Decreased uptake
The decrease in the uptake of antibiotics is due
to efflux pumps of bacteria, which drain the
antibiotics in the bacterial cell.10 Overexpression of
efflux pumps in a cell leads to the development of
resistance in bacteria [Figure 2]. This mechanism
particularly confers resistance to Staphylococci
against quinolones.

Figure 2: Decreased uptake of antibiotics.

How to resolve antibiotic resistance?
As the antibiotic resistance is posing serious threats
to the health of individuals, finding a right solution
is very much necessary to save the people.11 Proper
preventive steps have to be taken to decrease
the misuse of antibiotics. There is also a need
to develop strategies by exploiting advances in
molecular biology for finding new ways of treating
the resistance strains. The preventive measures
include proper education, decrease the use of
antibiotics in livestock and control in prescribing
antibiotics. Treatment of resistant strains include
development of new antibiotics, vaccines, nonantibiotics and use of bacteriophages as described
by Ian A Mckay et. al.
28
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Figure 3: Strategies for overcoming antibiotic resistance.

A. Education
Sensitizing the clinicians and the pharmacists about
the pharmacokinetic parameters of drug is very
much essential. The inappropriate prescribing of
antibiotics leads to patient complications and the
inadequate dosing leads to resistance. Alertness
about the need of proper prescription of antibiotics
is very essential to reduce the overuse and misuse
of antibiotics. There is also a need to educate the
public regarding hygiene and the need of following
the prescription.12 Multidrug resistance is mainly
seen in hospital-acquired infections. Hence, there is
a need to educate the health workers about proper
disinfection and hygiene.
B. Novel antibiotics
The resistance to antibiotics has started due to
using limited class of compounds having very less
targets and mechanisms. The development of a new
class of antibiotics having complex mechanisms
is essential for combating the battle of resistance.
The pharmaceutical companies treat the antibiotics
as non-profitable drugs compared to the drugs
used to treat the chronic diseases, which created a
gap in the field of antibiotics discovery. Hence, the
pharmaceutical companies need to step up and scale
up the research done in the academia. Screening
new chemical entities from natural sources like soil
and plants helps in isolation of the new natural
antibiotics.13
Isolation and characterization of animal secretions,
which contain antimicrobial agents, can be helpful in
treating the resistant strainsThe examples include
indolicidin from cow and protegrin 1 from pig.14
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Even many microbes produce bioactive compounds
like antibiotics which on isolation may give a new
class of antibiotics.
Table-1: New class of antibiotics15
NAME OF THE DRUG

CLASS

Ceftolozane

Cephalosporins

Clazomicin

Aminoglycoside

Eravacycline

Fluorocycline

Brilacidin

-----

C. Bacteriophages
Bactriophages are the viruses that specifically
infect bacteria and the studies suggest the use of
bacteriophage for the treatment of drug resistant
strains, seems promising. The Polish studies
based on this has shown that they are effective
against systemic infections and mucosal infections.
The immunogenicity is less and is having good
bioavailability. This therapy is still in early stages of
the development and a thorough research is required
regarding the physiology of bacteriophages.
D. Virulence factors
Many bacteria release virulence factors which will
cause infections. The suppression of virulence
factors by using new compounds finds effective in
combinational therapy with antimicrobial agents.16
Suppression does not kill microbe but decreases the
emergence of resistance. The examples include the
usage of RNA III for neutralization of virulence
factors of Staphylococcus aureus. Balaban et. al.
described the use of this compound which showed
decrease in the size of lesion in mice. The development
of vaccine using powerful virulent factor may give
good results and used as a synergistic therapy with
suitable class of antibiotics.
E. Combinational therapy
Combining the agents having different modes
of action has shown a promise. For example, the
combination of a macrolide and a fluoroquinolone
or beta lactam and a tetracycline has been used in
HIV infections. The use of beta lactamase inhibitors
along with beta lactam antibiotics is a good strategy.
Clavulanic acid is used as a beta lactamase inhibitor.

F. Non-antibiotics
Use of the class of drugs other than antibiotics
called non-antibiotics, is a hope for treating the
drug resistance. Compound like phenothiazines
might enhance the activity of the normal class of
antibiotics and useful in eliminating the resistance.
In some studies, they have shown activity against
the resistant bacterial strains.
G. Disruption of the biofilms
Certain bacteria are capable of producing polymers
which can shield them from immune cells. These
are called biofilms and the antibiotic resistance
conferred due to this is a difficult problem to treat.
It is because of the difference in the pattern of
resistance in biofilms and conventional microbes.17
Understanding the mechanisms in resistance hold
the key for developing the strategies against it. The
matrix surrounding bacteria is essential for their
survival. The use of substances that are capable of
destroying biofilm can be given as a combinational
therapy along with the conventional therapeutic
agents.18 Identifying the polymer in different kinds
of bacterial films is essential for choosing the agent
to depolymerize it, which is a promising area of
research.
Conclusion
The antibiotic resistance is a leading global crisis
developed due to the lack of new class of antibiotic
drugs and the misuse of the existing antibiotics. The
research in the area of development of new classes
of drugs like non-antibiotics, vaccines made of
potential virulence factors and use of bacteriophages
will be helpful in combating the battle of resistance.
At the same time, educating the health workers
and the public regarding self-medication, self-care,
and limiting the irrational prescription, dispensing,
and use of antibiotics is highly opted to overcome
the biggest challenge of the current century, the
antibiotic resistance.
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